Precede Biosciences

#NEVYs24: We’re excited to share that Precede Biosciences has been nominated for Emerging Life Sciences Company of the Year by the New England Venture Capital Association! We're proud to be part of this esteemed group of innovators and look forward to attending the awards ceremony on December 5! Check out the full nominee list here: bit.ly/48yZ7pV #NEVCA #Innovation #PrecisionMedicine

We are pleased to announce the speakers for our upcoming webinar, Emerging Applications and Platforms in Liquid Biopsy, on Wednesday, November 6, 2024. Join us for this discussion led by: Rehan Verjee, Chief Executive Officer, Precede Biosciences Dawn Mattoon, Chief Executive Officer, Mercy BioAnalytics, Inc. Peter B., Chief Medical Officer, DELFI Diagnostics Sarah Clancey Overton, Director of RCM, Velsera Mark Sausen, Executive Director, Head of Technology Innovation, PGDx, Labcorp Together, our distinguished speakers will explore advancements in liquid biopsy, including innovations in early cancer detection, epigenomics, and targeted therapies, while addressing challenges in access and reimbursement. Webinar Details 📅 Date: Wednesday, November 6, 2024 ⏰ Time: 9:00 AM - 10:00 AM PST 🔗Register here: https://lnkd.in/gKZBQanP #precisionmedicine #liquidbiopsy

Professor A. Oliver Sartor, MD, of Mayo Clinic sat down with our collaborator Jacob Berchuck, MD, medical oncologist at Winship Cancer Institute of Emory University for a video Q&A session on our recent ESMO data: Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform. "With myriad drugs in development targeting a wide array of cancer-enriched cell surface proteins, the results highlight the potential of epigenomic cfDNA profiling as a real-time, non-invasive readout of tumor drug target expression." -Dr. Berchuck "You have a genome-wide assessment and I think you could learn an enormous amount by looking at the PLUVICTO patients, both the responsive patients as well as the resistant patients." -Professor Sartor Thank you both for the engaging interview in UroToday + GU OncToday: https://bit.ly/3XQpD9l We have a lot of important and exciting work ahead of us as you both discussed, work that we hope will one day make it easier to get the right medicines to the right patients. #ProstateCancer #Epigenomics #PrecisionMedicine #DrugDevelopment #LiquidBiopsy Thank you to Aparna Gorthi and Anthony D'Ippolito of Precede Biosciences for their leadership and collaboration on the ESMO work.

Want to learn more about the relevance of detecting PSMA positivity in advanced prostate cancer patients from a simple blood test? Check out this great interview in Targeted Oncology with our collaborator Dr. Jacob Berchuck. https://bit.ly/4e7gBvE #ProstateCancer #Epigenomics #PrecisionMedicine #DrugDevelopment

Thank you Corrie Painter and Dr. Laura Airas for presenting data today at #ECTRIMS2024. And, a special thank you to all who came by to see what we’re up to. #FutureSoBrightGottaWearShades

Precede Biosciences is excited to share data at #ECTRIMS2024 underscoring the potential to leverage comprehensive epigenomic profiling from a simple blood test to reveal central nervous system disease biology for #MS. View press release: https://bit.ly/4d9JNRn. #PrecisionMedicine #LiquidBiopsy #DrugDevelopment

#ECTRIMS2024 starts today! If you're in Copenhagen and want to learn more about the potential for comprehensive epigenomic profiling to reveal disease biology, meet Precede Biosciences' Corrie Painter at our poster presentation (#P762) on Thursday, September 19 at 16:45 CET. https://bit.ly/4geKpI8 #PrecisionMedicine #LiquidBiopsy #MS

Watch as Aparna Gorthi goes Behind the Science at #ESMO24 to describe the potential of Precede Biosciences' comprehensive epigenomic #LiquidBiopsy platform to reveal tumor expression of PSMA and other therapeutically relevant targets from a simple blood test. View data: https://bit.ly/4e3bdd2 #PrecisionMedicine #PrecisionOncology #DrugDevelopment #ProstateCancer #OncoAlert

Thank you to everyone who stopped by the poster at #ESMO24 to hear Dr. Jacob Berchuck and Precede Biosciences present new data on the power of our comprehensive #LiquidBiopsy platform to reveal tumor PSMA expression from a simple blood test. View poster: https://bit.ly/4e3bdd2  #PrecisionMedicine #ProstateCancer

Precede Biosciences is excited to share data at #ESMO24 demonstrating our unique platform’s capability to reveal tumor PSMA expression from a simple blood test that is highly correlated with PSMA-PET imaging. View press release: https://bit.ly/47oot9z #PrecisionMedicine #Healthcare #DrugDevelopment #ProstateCancer